Ampersand Capital Partners, which invests in healthcare companies in the middle market, closed a majority recapitalization of New England Peptide Inc.
The Gardner, Mass.-headquartered company designs and manufactures peptide and antibody solutions for drug, vaccine and diagnostic development organizations across the globe.
José de Chastonay, who most recently was chief marketing officer and corporate executive committee member at Bachem Holding AG, joined New England Peptide's board as executive chairman.
